title: Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas.
abstract: As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An overall partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: J P
authors.initials: JP
authors.lastname: Crown
authors.forename: S
authors.initials: S
authors.lastname: Gulati
authors.forename: D J
authors.initials: DJ
authors.lastname: Straus
authors.forename: J
authors.initials: J
authors.lastname: Kolitz
authors.forename: R
authors.initials: R
authors.lastname: Heelan
authors.forename: J
authors.initials: J
authors.lastname: O'Brien
authors.forename: B J
authors.initials: BJ
authors.lastname: Lee
authors.forename: C
authors.initials: C
authors.lastname: Portlock
authors.forename: J
authors.initials: J
authors.lastname: Bertino
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008875:Middle Aged; D008935:Mitoguazone / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014747:Vinblastine; D005047:Etoposide; D008942:Mitoxantrone; D008935:Mitoguazone